SCHEMBL29359283

SCHEMBL29359283

CCOC(=O)N(CC(C)(C)NC(=O)OC(C)(C)C)C1(c2ccc(F)c(C(F)(F)F)c2)CC1

nearest known ligand 0.72

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 8/20 0.72
RORC P51449 7/20 0.35
AAK1 Q2M2I8 3/20 0.33
AR P10275 1/20 0.32
DRD2 P14416 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29353607 0.92 KCNN4 (0.72) KCNN4RORCAAK1ARDRD2
SCHEMBL22470161 0.89 KCNN4 (0.59) KCNN4RORCARDRD2
SCHEMBL29354486 0.85 KCNN4 (0.55) KCNN4RORCAR
SCHEMBL29353543 0.84 KCNN4 (1.00) KCNN4AR
SCHEMBL29356985 0.81 KCNN4 (0.66) KCNN4RORCAR
SCHEMBL29356770 0.81 KCNN4 (0.76) KCNN4RORCAR
SCHEMBL29356955 0.80 KCNN4 (0.65) KCNN4RORCAR
SCHEMBL29699684 0.80 KCNN4 (0.74) KCNN4AAK1DRD2
SCHEMBL29353670 0.79 KCNN4 (0.79) KCNN4AR
SCHEMBL22470482 0.77 KCNN4 (0.60) KCNN4RORCAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049054-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA AS (DK) 2026-02-19 US disclosed
US-12391644-B2 Potassium channel inhibitors SANIONA A/S (DK) 2025-08-19 US disclosed
EP-3941903-B1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA AS (DK) 2025-07-16 EP disclosed
US-20240368077-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA AS (DK) 2024-11-07 US disclosed
US-12006289-B2 Potassium channel inhibitors SANIONA A/S (DK) 2024-06-11 US disclosed
US-20220169602-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2022-06-02 US disclosed
EP-3941903-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Saniona A/S (DK) 2022-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391644-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 KCNN4 48/4885RORC 2789/4885AAK1 858/4885
US-20240368077-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 KCNN4 57/4885RORC 2964/4885AAK1 676/4885
US-20220169602-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 KCNN4 57/4885RORC 2964/4885AAK1 676/4885
US-12006289-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 KCNN4 48/4885RORC 2789/4885AAK1 858/4885
US-20260049054-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SCN10A, KCNK10, KCNJ2 KCNN4 43/4885RORC 4489/4885AAK1 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.